Parexel strengthens presence in Europe
US contract research organization Parexel International has openedadditional offices in Belgium (Brussels) Germany (Munich) and Romania (Bucharest) to further expand "its ability to deliver comprehensive biopharmaceutical outsourcing services to clients worldwide," the company said. Parexel, which has over 4,640 employees, notes that it already operates in 54 locations throughout 35 countries around the world.
Parexel's president, Carl Spalding, said "these new offices have been opened to meet our clients' needs for global expertise and knowledge of local country regulatory and clinical practices," adding that he believes his company has the largest CRO presence on the European continent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze